Last edition
News about "Median Technologies partners Tempus AI"
Median Technologies, a France-based developer of artificial intelligence-powered software as a medical device, has entered a non-exclusive distribution agreement with Tempus AI, Inc. to commercialise its Eyonis LCS lung screening platform in the United States.
Median Technologies Partners Tempus AI | 15/02/2026 | By Darshana
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members